cytosine has been researched along with Eye Infections, Viral in 18 studies
Eye Infections, Viral: Infections of the eye caused by minute intracellular agents. These infections may lead to severe inflammation in various parts of the eye - conjunctiva, iris, eyelids, etc. Several viruses have been identified as the causative agents. Among these are Herpesvirus, Adenovirus, Poxvirus, and Myxovirus.
| Excerpt | Relevance | Reference |
|---|---|---|
| "2% cidofovir eyedrops and 1% cyclosporine eyedrops administered 4 times daily (qid) to treat acute adenoviral keratoconjunctivitis." | 9.09 | Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a controlled clinical pilot study. ( Böhringer, D; Cartsburg, O; De Clercq, E; Godehardt, E; Hillenkamp, J; Reinhard, T; Roggendorf, M; Ross, RS; Sundmacher, R, 2001) |
| "To report use of intravenous foscarnet or cidofovir for the treatment of refractory acute retinal necrosis (ARN)." | 7.88 | Treatment of Refractory Acute Retinal Necrosis with Intravenous Foscarnet or Cidofovir. ( Barshak, MB; Durand, ML; Foster, CS; Kim, IK; Mali, JO; Scott, NL; Stryjewski, TP; Tobin, EH; Young, LH, 2018) |
| "The effect of liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC; cidofovir) was evaluated as prophylaxis in a rabbit model of experimentally induced retinitis caused by preretinal inoculation of herpes simplex virus type 1 (HSV-1)." | 7.69 | Liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for long-acting therapy of viral retinitis. ( Assil, KK; Bergeron-Lynn, G; Besen, G; Connor, JD; De Clercq, E; Freeman, WR; Kuppermann, BD; Munguia, D; Pursley, M; Vuong, C; Wiley, CA, 1996) |
| "2% cidofovir eyedrops and 1% cyclosporine eyedrops administered 4 times daily (qid) to treat acute adenoviral keratoconjunctivitis." | 5.09 | Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a controlled clinical pilot study. ( Böhringer, D; Cartsburg, O; De Clercq, E; Godehardt, E; Hillenkamp, J; Reinhard, T; Roggendorf, M; Ross, RS; Sundmacher, R, 2001) |
| "To report use of intravenous foscarnet or cidofovir for the treatment of refractory acute retinal necrosis (ARN)." | 3.88 | Treatment of Refractory Acute Retinal Necrosis with Intravenous Foscarnet or Cidofovir. ( Barshak, MB; Durand, ML; Foster, CS; Kim, IK; Mali, JO; Scott, NL; Stryjewski, TP; Tobin, EH; Young, LH, 2018) |
| "To evaluate(s)-1-(3-hydroxy-2-phosphonyl methoxypropyl) cytosine (HPMPC), a potent antiherpes and anticytomegalovirus drug, as a long-term treatment of experimental retinitis in rabbits." | 3.69 | Long-term therapy for herpes retinitis in an animal model with high-concentrated liposome-encapsulated HPMPC. ( Assil, KK; Bergeron-Lynn, G; Besen, G; De Clercq, E; Flores-Aguilar, M; Gangan, P; Kupperman, BD; Munguia, D; Pursley, M; Vuong, C, 1995) |
| "The effect of liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC; cidofovir) was evaluated as prophylaxis in a rabbit model of experimentally induced retinitis caused by preretinal inoculation of herpes simplex virus type 1 (HSV-1)." | 3.69 | Liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for long-acting therapy of viral retinitis. ( Assil, KK; Bergeron-Lynn, G; Besen, G; Connor, JD; De Clercq, E; Freeman, WR; Kuppermann, BD; Munguia, D; Pursley, M; Vuong, C; Wiley, CA, 1996) |
| " Further clinical studies to find an efficacious yet tolerable dosage regimen of cidofovir, possibly using an improved pharmaceutical preparation, are required." | 2.70 | The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study. ( Böhringer, D; Cartsburg, O; De Clercq, E; Godehardt, E; Hillenkamp, J; Reinhard, T; Roggendorf, M; Ross, RS; Sundmacher, R, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 10 (55.56) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zirofsky, D | 1 |
| Rekers, W | 1 |
| Powell, C | 1 |
| Hawley, J | 1 |
| Veir, J | 1 |
| Lappin, M | 1 |
| Graef, S | 1 |
| Kurth, A | 1 |
| Auw-Haedrich, C | 1 |
| Plange, N | 1 |
| Kern, WV | 1 |
| Nitsche, A | 1 |
| Reinhard, T | 3 |
| Stryjewski, TP | 1 |
| Scott, NL | 1 |
| Barshak, MB | 1 |
| Tobin, EH | 1 |
| Mali, JO | 1 |
| Young, LH | 1 |
| Foster, CS | 1 |
| Kim, IK | 1 |
| Durand, ML | 1 |
| Garneau, M | 1 |
| Bolger, GT | 1 |
| Bousquet, C | 1 |
| Kibler, P | 1 |
| Tremblay, F | 1 |
| Cordingley, MG | 1 |
| Kaneko, H | 1 |
| Mori, S | 1 |
| Suzuki, O | 1 |
| Iida, T | 1 |
| Shigeta, S | 1 |
| Abe, M | 1 |
| Ohno, S | 1 |
| Aoki, K | 1 |
| Suzutani, T | 1 |
| Cheng, L | 1 |
| Hostetler, KY | 1 |
| Lee, J | 1 |
| Koh, HJ | 1 |
| Beadle, JR | 1 |
| Bessho, K | 1 |
| Toyoguchi, M | 1 |
| Aldern, K | 1 |
| Bovet, JM | 1 |
| Freeman, WR | 2 |
| Romanowski, EG | 5 |
| Yates, KA | 1 |
| Teuchner, B | 1 |
| Nagl, M | 1 |
| Irschick, EU | 1 |
| Gordon, YJ | 6 |
| Nwanegbo, EC | 1 |
| Gambotto, A | 1 |
| Besen, G | 2 |
| Flores-Aguilar, M | 1 |
| Assil, KK | 2 |
| Kupperman, BD | 1 |
| Gangan, P | 1 |
| Pursley, M | 2 |
| Munguia, D | 2 |
| Vuong, C | 2 |
| De Clercq, E | 5 |
| Bergeron-Lynn, G | 2 |
| Araullo-Cruz, T | 2 |
| Kuppermann, BD | 1 |
| Wiley, CA | 1 |
| Connor, JD | 1 |
| Hillenkamp, J | 2 |
| Ross, RS | 2 |
| Böhringer, D | 2 |
| Cartsburg, O | 2 |
| Roggendorf, M | 2 |
| Godehardt, E | 2 |
| Sundmacher, R | 2 |
| Chakrabarti, S | 1 |
| Collingham, KE | 1 |
| Osman, H | 1 |
| Fegan, CD | 1 |
| Milligan, DW | 1 |
| Romanowski, E | 1 |
2 trials available for cytosine and Eye Infections, Viral
| Article | Year |
|---|---|
Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a controlled clinical pilot study.
Topics: Acute Disease; Adenovirus Infections, Human; Adenoviruses, Human; Administration, Topical; Adult; Ag | 2001 |
The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study.
Topics: Acute Disease; Adenovirus Infections, Human; Adenoviruses, Human; Adult; Aged; Aged, 80 and over; An | 2002 |
16 other studies available for cytosine and Eye Infections, Viral
| Article | Year |
|---|---|
Feline Herpesvirus 1 and Mycoplasma spp. Conventional PCR Assay Results From Conjunctival Samples From Cats in Shelters With Suspected Acute Ocular Infections.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Antiviral Agents; Cat Diseases; Cats; Cidofovir; Conj | 2018 |
Clinicopathological findings in persistent corneal cowpox infection.
Topics: Antiviral Agents; Cidofovir; Combined Modality Therapy; Corneal Ulcer; Cowpox; Cowpox virus; Cytosin | 2013 |
Treatment of Refractory Acute Retinal Necrosis with Intravenous Foscarnet or Cidofovir.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Cidofovir; Cytosine; Eye Infections, Viral; Foscarnet; He | 2018 |
HPMPC therapy of MCMV-induced retinal disease in the SCID mouse measured by electroretinography, a non-invasive technique.
Topics: Animals; Antiviral Agents; Cidofovir; Cytomegalovirus Retinitis; Cytosine; Disease Models, Animal; E | 2003 |
The cotton rat model for adenovirus ocular infection: antiviral activity of cidofovir.
Topics: Adenoviridae Infections; Adenoviruses, Human; Administration, Topical; Animals; Antigens, Viral; Ant | 2004 |
Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir.
Topics: Animals; Antiviral Agents; Area Under Curve; Biological Availability; Chromatography, High Pressure | 2004 |
N-chlorotaurine is an effective antiviral agent against adenovirus in vitro and in the Ad5/NZW rabbit ocular model.
Topics: Adenoviridae; Adenoviridae Infections; Animals; Antiviral Agents; Cidofovir; Cornea; Cytosine; Disea | 2006 |
Efficacy of topical immunoglobulins against experimental adenoviral ocular infection.
Topics: Adenovirus Infections, Human; Adenoviruses, Human; Administration, Topical; Animals; Antiviral Agent | 2007 |
Long-term therapy for herpes retinitis in an animal model with high-concentrated liposome-encapsulated HPMPC.
Topics: Animals; Antiviral Agents; Cidofovir; Cytosine; Disease Models, Animal; Electroretinography; Eye Inf | 1995 |
Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model.
Topics: Adenoviridae Infections; Adenoviruses, Human; Animals; Antiviral Agents; Cidofovir; Cytosine; Eye In | 1994 |
Liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for long-acting therapy of viral retinitis.
Topics: Animals; Antiviral Agents; Cidofovir; Cytosine; Disease Models, Animal; Drug Carriers; Eye Infection | 1996 |
Drugs for non-HIV viral infections.
Topics: 2-Aminopurine; Abnormalities, Drug-Induced; Acyclovir; Amantadine; Antiviral Agents; Cidofovir; Cont | 1997 |
Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model.
Topics: Adenovirus Infections, Human; Adenoviruses, Human; Administration, Topical; Animals; Antiviral Agent | 2000 |
Effects of diclofenac or ketorolac on the inhibitory activity of cidofovir in the Ad5/NZW rabbit model.
Topics: Adenovirus Infections, Human; Adenoviruses, Human; Animals; Anti-Inflammatory Agents, Non-Steroidal; | 2001 |
Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.
Topics: Adult; Antiviral Agents; Cidofovir; Cyclosporine; Cytomegalovirus; Cytomegalovirus Infections; Cytos | 2001 |
Pretreatment with topical 0.1% (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine inhibits adenovirus type 5 replication in the New Zealand rabbit ocular model.
Topics: Adenoviridae; Adenoviridae Infections; Animals; Antiviral Agents; Cidofovir; Colony Count, Microbial | 1992 |